nodes	percent_of_prediction	percent_of_DWPC	metapath
Mometasone—CYP2C8—Fluorouracil—urinary bladder cancer	0.0465	0.545	CbGbCtD
Mometasone—CYP2C8—Etoposide—urinary bladder cancer	0.0388	0.455	CbGbCtD
Mometasone—NR3C1—Endoderm Differentiation—BPTF—urinary bladder cancer	0.00772	0.066	CbGpPWpGaD
Mometasone—NR3C1—urine—urinary bladder cancer	0.00719	0.26	CbGeAlD
Mometasone—CYP2C8—Tamoxifen metabolism—UGT2B7—urinary bladder cancer	0.0064	0.0547	CbGpPWpGaD
Mometasone—CYP2C8—Oxidation by Cytochrome P450—POR—urinary bladder cancer	0.00519	0.0444	CbGpPWpGaD
Mometasone—NR3C1—Signaling events mediated by HDAC Class II—HDAC4—urinary bladder cancer	0.00511	0.0436	CbGpPWpGaD
Mometasone—CYP2C8—Arachidonate Epoxygenase / Epoxide Hydrolase—GSTP1—urinary bladder cancer	0.00496	0.0424	CbGpPWpGaD
Mometasone—NR3C1—Glucocorticoid receptor regulatory network—KRT5—urinary bladder cancer	0.00349	0.0298	CbGpPWpGaD
Mometasone—NR3C1—AP-1 transcription factor network—MT2A—urinary bladder cancer	0.00295	0.0252	CbGpPWpGaD
Mometasone—CYP2C8—Arachidonic acid metabolism—CYP4B1—urinary bladder cancer	0.00288	0.0246	CbGpPWpGaD
Mometasone—NR3C1—prostate gland—urinary bladder cancer	0.00258	0.0934	CbGeAlD
Mometasone—NR3C1—FOXA2 and FOXA3 transcription factor networks—TFRC—urinary bladder cancer	0.0025	0.0214	CbGpPWpGaD
Mometasone—CYP2C8—Cytochrome P450 - arranged by substrate type—CYP4B1—urinary bladder cancer	0.00249	0.0213	CbGpPWpGaD
Mometasone—NR3C1—Nuclear Receptors—ESR2—urinary bladder cancer	0.00248	0.0212	CbGpPWpGaD
Mometasone—CYP2C8—Oxidation by Cytochrome P450—CYP4B1—urinary bladder cancer	0.00246	0.021	CbGpPWpGaD
Mometasone—Urinary tract infection—Fluorouracil—urinary bladder cancer	0.00231	0.003	CcSEcCtD
Mometasone—Conjunctivitis—Fluorouracil—urinary bladder cancer	0.00231	0.003	CcSEcCtD
Mometasone—Rash—Mitomycin—urinary bladder cancer	0.0023	0.00299	CcSEcCtD
Mometasone—Dermatitis—Mitomycin—urinary bladder cancer	0.0023	0.00298	CcSEcCtD
Mometasone—Skin discolouration—Epirubicin—urinary bladder cancer	0.00229	0.00298	CcSEcCtD
Mometasone—Viral infection—Epirubicin—urinary bladder cancer	0.00229	0.00298	CcSEcCtD
Mometasone—Headache—Mitomycin—urinary bladder cancer	0.00228	0.00297	CcSEcCtD
Mometasone—Bronchospasm—Etoposide—urinary bladder cancer	0.00228	0.00296	CcSEcCtD
Mometasone—Epistaxis—Fluorouracil—urinary bladder cancer	0.00224	0.00291	CcSEcCtD
Mometasone—Sinusitis—Fluorouracil—urinary bladder cancer	0.00223	0.0029	CcSEcCtD
Mometasone—Conjunctivitis—Cisplatin—urinary bladder cancer	0.00219	0.00285	CcSEcCtD
Mometasone—Ulcer—Epirubicin—urinary bladder cancer	0.00219	0.00284	CcSEcCtD
Mometasone—NR3C1—seminal vesicle—urinary bladder cancer	0.00218	0.079	CbGeAlD
Mometasone—Rhinitis—Gemcitabine—urinary bladder cancer	0.00218	0.00283	CcSEcCtD
Mometasone—Back pain—Thiotepa—urinary bladder cancer	0.00217	0.00282	CcSEcCtD
Mometasone—Nausea—Mitomycin—urinary bladder cancer	0.00216	0.00281	CcSEcCtD
Mometasone—Pharyngitis—Gemcitabine—urinary bladder cancer	0.00215	0.0028	CcSEcCtD
Mometasone—Rhinitis—Fluorouracil—urinary bladder cancer	0.00214	0.00278	CcSEcCtD
Mometasone—NR3C1—Transcription factor regulation in adipogenesis—PPARG—urinary bladder cancer	0.00212	0.0181	CbGpPWpGaD
Mometasone—Skin discolouration—Doxorubicin—urinary bladder cancer	0.00212	0.00275	CcSEcCtD
Mometasone—Viral infection—Doxorubicin—urinary bladder cancer	0.00212	0.00275	CcSEcCtD
Mometasone—Pharyngitis—Fluorouracil—urinary bladder cancer	0.00212	0.00275	CcSEcCtD
Mometasone—Musculoskeletal pain—Epirubicin—urinary bladder cancer	0.00209	0.00272	CcSEcCtD
Mometasone—Dermatitis contact—Epirubicin—urinary bladder cancer	0.00204	0.00266	CcSEcCtD
Mometasone—Ulcer—Doxorubicin—urinary bladder cancer	0.00202	0.00263	CcSEcCtD
Mometasone—CYP2C8—Phase 1 - Functionalization of compounds—CYP4B1—urinary bladder cancer	0.00202	0.0172	CbGpPWpGaD
Mometasone—Influenza like illness—Epirubicin—urinary bladder cancer	0.00201	0.00261	CcSEcCtD
Mometasone—Candida infection—Epirubicin—urinary bladder cancer	0.00197	0.00257	CcSEcCtD
Mometasone—CYP2C8—renal system—urinary bladder cancer	0.00196	0.0711	CbGeAlD
Mometasone—Immune system disorder—Gemcitabine—urinary bladder cancer	0.00196	0.00255	CcSEcCtD
Mometasone—Cough—Thiotepa—urinary bladder cancer	0.00196	0.00255	CcSEcCtD
Mometasone—NR3C1—Nuclear Receptor transcription pathway—ESR2—urinary bladder cancer	0.00196	0.0167	CbGpPWpGaD
Mometasone—Mediastinal disorder—Gemcitabine—urinary bladder cancer	0.00196	0.00254	CcSEcCtD
Mometasone—NR3C1—BMAL1:CLOCK,NPAS2 activates circadian gene expression—NCOR1—urinary bladder cancer	0.00195	0.0167	CbGpPWpGaD
Mometasone—Musculoskeletal pain—Doxorubicin—urinary bladder cancer	0.00194	0.00252	CcSEcCtD
Mometasone—Arthralgia—Thiotepa—urinary bladder cancer	0.00191	0.00249	CcSEcCtD
Mometasone—Myalgia—Thiotepa—urinary bladder cancer	0.00191	0.00249	CcSEcCtD
Mometasone—NR3C1—epithelium—urinary bladder cancer	0.0019	0.0686	CbGeAlD
Mometasone—Dermatitis contact—Doxorubicin—urinary bladder cancer	0.00189	0.00246	CcSEcCtD
Mometasone—Influenza like illness—Doxorubicin—urinary bladder cancer	0.00186	0.00242	CcSEcCtD
Mometasone—Back pain—Gemcitabine—urinary bladder cancer	0.00183	0.00238	CcSEcCtD
Mometasone—Candida infection—Doxorubicin—urinary bladder cancer	0.00183	0.00238	CcSEcCtD
Mometasone—Immune system disorder—Cisplatin—urinary bladder cancer	0.00183	0.00237	CcSEcCtD
Mometasone—NR3C1—smooth muscle tissue—urinary bladder cancer	0.00183	0.0661	CbGeAlD
Mometasone—Mediastinal disorder—Cisplatin—urinary bladder cancer	0.00182	0.00237	CcSEcCtD
Mometasone—Infection—Thiotepa—urinary bladder cancer	0.00182	0.00237	CcSEcCtD
Mometasone—NR3C1—renal system—urinary bladder cancer	0.00176	0.0637	CbGeAlD
Mometasone—Anorexia—Thiotepa—urinary bladder cancer	0.00175	0.00227	CcSEcCtD
Mometasone—NR3C1—urethra—urinary bladder cancer	0.00173	0.0625	CbGeAlD
Mometasone—Immune system disorder—Etoposide—urinary bladder cancer	0.00167	0.00218	CcSEcCtD
Mometasone—Mediastinal disorder—Etoposide—urinary bladder cancer	0.00167	0.00217	CcSEcCtD
Mometasone—Musculoskeletal discomfort—Thiotepa—urinary bladder cancer	0.00167	0.00217	CcSEcCtD
Mometasone—Cough—Gemcitabine—urinary bladder cancer	0.00165	0.00214	CcSEcCtD
Mometasone—Paraesthesia—Thiotepa—urinary bladder cancer	0.00165	0.00214	CcSEcCtD
Mometasone—Dyspepsia—Thiotepa—urinary bladder cancer	0.00161	0.0021	CcSEcCtD
Mometasone—Arthralgia—Gemcitabine—urinary bladder cancer	0.00161	0.00209	CcSEcCtD
Mometasone—Chest pain—Gemcitabine—urinary bladder cancer	0.00161	0.00209	CcSEcCtD
Mometasone—Myalgia—Gemcitabine—urinary bladder cancer	0.00161	0.00209	CcSEcCtD
Mometasone—Decreased appetite—Thiotepa—urinary bladder cancer	0.00159	0.00207	CcSEcCtD
Mometasone—Chest pain—Fluorouracil—urinary bladder cancer	0.00158	0.00206	CcSEcCtD
Mometasone—Myalgia—Fluorouracil—urinary bladder cancer	0.00158	0.00206	CcSEcCtD
Mometasone—Fatigue—Thiotepa—urinary bladder cancer	0.00158	0.00205	CcSEcCtD
Mometasone—CYP2C8—female reproductive system—urinary bladder cancer	0.00157	0.0569	CbGeAlD
Mometasone—Pain—Thiotepa—urinary bladder cancer	0.00157	0.00204	CcSEcCtD
Mometasone—Back pain—Etoposide—urinary bladder cancer	0.00156	0.00203	CcSEcCtD
Mometasone—Anaphylactic shock—Gemcitabine—urinary bladder cancer	0.00154	0.002	CcSEcCtD
Mometasone—CYP2C8—Arachidonic acid metabolism—HPGDS—urinary bladder cancer	0.00153	0.0131	CbGpPWpGaD
Mometasone—Infection—Gemcitabine—urinary bladder cancer	0.00153	0.00199	CcSEcCtD
Mometasone—Anaphylactic shock—Fluorouracil—urinary bladder cancer	0.00152	0.00197	CcSEcCtD
Mometasone—Infection—Fluorouracil—urinary bladder cancer	0.00151	0.00196	CcSEcCtD
Mometasone—NR3C1—Signaling events mediated by HDAC Class II—ESR1—urinary bladder cancer	0.0015	0.0128	CbGpPWpGaD
Mometasone—NR3C1—Nuclear Receptors—ESR1—urinary bladder cancer	0.0015	0.0128	CbGpPWpGaD
Mometasone—Myalgia—Cisplatin—urinary bladder cancer	0.0015	0.00195	CcSEcCtD
Mometasone—Gastrointestinal pain—Thiotepa—urinary bladder cancer	0.0015	0.00195	CcSEcCtD
Mometasone—Anorexia—Gemcitabine—urinary bladder cancer	0.00147	0.00191	CcSEcCtD
Mometasone—Body temperature increased—Thiotepa—urinary bladder cancer	0.00145	0.00188	CcSEcCtD
Mometasone—Abdominal pain—Thiotepa—urinary bladder cancer	0.00145	0.00188	CcSEcCtD
Mometasone—Anorexia—Fluorouracil—urinary bladder cancer	0.00144	0.00188	CcSEcCtD
Mometasone—Anaphylactic shock—Cisplatin—urinary bladder cancer	0.00144	0.00187	CcSEcCtD
Mometasone—Infection—Cisplatin—urinary bladder cancer	0.00143	0.00186	CcSEcCtD
Mometasone—NR3C1—Circadian Clock—NCOR1—urinary bladder cancer	0.00142	0.0122	CbGpPWpGaD
Mometasone—CYP2C8—vagina—urinary bladder cancer	0.00142	0.0515	CbGeAlD
Mometasone—NR3C1—female reproductive system—urinary bladder cancer	0.00141	0.051	CbGeAlD
Mometasone—Cough—Etoposide—urinary bladder cancer	0.00141	0.00183	CcSEcCtD
Mometasone—Musculoskeletal discomfort—Gemcitabine—urinary bladder cancer	0.0014	0.00183	CcSEcCtD
Mometasone—Asthma—Methotrexate—urinary bladder cancer	0.00139	0.0018	CcSEcCtD
Mometasone—Paraesthesia—Gemcitabine—urinary bladder cancer	0.00138	0.0018	CcSEcCtD
Mometasone—Musculoskeletal discomfort—Fluorouracil—urinary bladder cancer	0.00138	0.0018	CcSEcCtD
Mometasone—Dyspnoea—Gemcitabine—urinary bladder cancer	0.00137	0.00179	CcSEcCtD
Mometasone—Chest pain—Etoposide—urinary bladder cancer	0.00137	0.00179	CcSEcCtD
Mometasone—CYP2C8—Biological oxidations—GSTZ1—urinary bladder cancer	0.00137	0.0117	CbGpPWpGaD
Mometasone—NR3C1—Nuclear Receptors—PPARG—urinary bladder cancer	0.00137	0.0117	CbGpPWpGaD
Mometasone—Anorexia—Cisplatin—urinary bladder cancer	0.00137	0.00178	CcSEcCtD
Mometasone—Paraesthesia—Fluorouracil—urinary bladder cancer	0.00136	0.00177	CcSEcCtD
Mometasone—CYP2C8—Metapathway biotransformation—GSTZ1—urinary bladder cancer	0.00135	0.0116	CbGpPWpGaD
Mometasone—Dyspnoea—Fluorouracil—urinary bladder cancer	0.00135	0.00176	CcSEcCtD
Mometasone—NR3C1—BMAL1:CLOCK,NPAS2 activates circadian gene expression—CREBBP—urinary bladder cancer	0.00134	0.0115	CbGpPWpGaD
Mometasone—Nasopharyngitis—Epirubicin—urinary bladder cancer	0.00134	0.00175	CcSEcCtD
Mometasone—Decreased appetite—Gemcitabine—urinary bladder cancer	0.00134	0.00174	CcSEcCtD
Mometasone—Dyspepsia—Fluorouracil—urinary bladder cancer	0.00133	0.00173	CcSEcCtD
Mometasone—Fatigue—Gemcitabine—urinary bladder cancer	0.00133	0.00173	CcSEcCtD
Mometasone—Pain—Gemcitabine—urinary bladder cancer	0.00132	0.00171	CcSEcCtD
Mometasone—Decreased appetite—Fluorouracil—urinary bladder cancer	0.00132	0.00171	CcSEcCtD
Mometasone—Anaphylactic shock—Etoposide—urinary bladder cancer	0.00132	0.00171	CcSEcCtD
Mometasone—Asthenia—Thiotepa—urinary bladder cancer	0.00131	0.00171	CcSEcCtD
Mometasone—Musculoskeletal discomfort—Cisplatin—urinary bladder cancer	0.00131	0.0017	CcSEcCtD
Mometasone—Infection—Etoposide—urinary bladder cancer	0.00131	0.0017	CcSEcCtD
Mometasone—CYP2C8—Biological oxidations—GSTO2—urinary bladder cancer	0.0013	0.0111	CbGpPWpGaD
Mometasone—CYP2C8—Biological oxidations—NAT1—urinary bladder cancer	0.0013	0.0111	CbGpPWpGaD
Mometasone—Influenza—Epirubicin—urinary bladder cancer	0.0013	0.00169	CcSEcCtD
Mometasone—Asthma—Epirubicin—urinary bladder cancer	0.0013	0.00169	CcSEcCtD
Mometasone—Pruritus—Thiotepa—urinary bladder cancer	0.0013	0.00169	CcSEcCtD
Mometasone—Pain—Fluorouracil—urinary bladder cancer	0.0013	0.00168	CcSEcCtD
Mometasone—Paraesthesia—Cisplatin—urinary bladder cancer	0.00129	0.00168	CcSEcCtD
Mometasone—Upper respiratory tract infection—Methotrexate—urinary bladder cancer	0.00129	0.00168	CcSEcCtD
Mometasone—CYP2C8—Metapathway biotransformation—GSTO2—urinary bladder cancer	0.00128	0.011	CbGpPWpGaD
Mometasone—Dyspnoea—Cisplatin—urinary bladder cancer	0.00128	0.00167	CcSEcCtD
Mometasone—NR3C1—vagina—urinary bladder cancer	0.00127	0.0461	CbGeAlD
Mometasone—Anorexia—Etoposide—urinary bladder cancer	0.00125	0.00163	CcSEcCtD
Mometasone—Diarrhoea—Thiotepa—urinary bladder cancer	0.00125	0.00163	CcSEcCtD
Mometasone—Decreased appetite—Cisplatin—urinary bladder cancer	0.00125	0.00162	CcSEcCtD
Mometasone—Bronchitis—Epirubicin—urinary bladder cancer	0.00125	0.00162	CcSEcCtD
Mometasone—Nasopharyngitis—Doxorubicin—urinary bladder cancer	0.00124	0.00161	CcSEcCtD
Mometasone—Pain—Cisplatin—urinary bladder cancer	0.00123	0.0016	CcSEcCtD
Mometasone—Body temperature increased—Gemcitabine—urinary bladder cancer	0.00122	0.00158	CcSEcCtD
Mometasone—Upper respiratory tract infection—Epirubicin—urinary bladder cancer	0.00121	0.00157	CcSEcCtD
Mometasone—Conjunctivitis—Methotrexate—urinary bladder cancer	0.0012	0.00156	CcSEcCtD
Mometasone—Influenza—Doxorubicin—urinary bladder cancer	0.0012	0.00156	CcSEcCtD
Mometasone—Asthma—Doxorubicin—urinary bladder cancer	0.0012	0.00156	CcSEcCtD
Mometasone—Body temperature increased—Fluorouracil—urinary bladder cancer	0.0012	0.00156	CcSEcCtD
Mometasone—CYP2C8—Biological oxidations—UGT2B7—urinary bladder cancer	0.00119	0.0102	CbGpPWpGaD
Mometasone—NR3C1—Nuclear Receptor transcription pathway—ESR1—urinary bladder cancer	0.00119	0.0101	CbGpPWpGaD
Mometasone—Paraesthesia—Etoposide—urinary bladder cancer	0.00118	0.00154	CcSEcCtD
Mometasone—CYP2C8—Metapathway biotransformation—UGT2B7—urinary bladder cancer	0.00117	0.01	CbGpPWpGaD
Mometasone—Dyspnoea—Etoposide—urinary bladder cancer	0.00117	0.00153	CcSEcCtD
Mometasone—Epistaxis—Methotrexate—urinary bladder cancer	0.00117	0.00152	CcSEcCtD
Mometasone—Vomiting—Thiotepa—urinary bladder cancer	0.00117	0.00151	CcSEcCtD
Mometasone—Rash—Thiotepa—urinary bladder cancer	0.00116	0.0015	CcSEcCtD
Mometasone—Bronchitis—Doxorubicin—urinary bladder cancer	0.00115	0.0015	CcSEcCtD
Mometasone—Dermatitis—Thiotepa—urinary bladder cancer	0.00115	0.0015	CcSEcCtD
Mometasone—Headache—Thiotepa—urinary bladder cancer	0.00115	0.00149	CcSEcCtD
Mometasone—Decreased appetite—Etoposide—urinary bladder cancer	0.00114	0.00149	CcSEcCtD
Mometasone—Body temperature increased—Cisplatin—urinary bladder cancer	0.00114	0.00148	CcSEcCtD
Mometasone—Fatigue—Etoposide—urinary bladder cancer	0.00113	0.00148	CcSEcCtD
Mometasone—NR3C1—Transcription factor regulation in adipogenesis—TNF—urinary bladder cancer	0.00113	0.00963	CbGpPWpGaD
Mometasone—Pain—Etoposide—urinary bladder cancer	0.00113	0.00146	CcSEcCtD
Mometasone—Conjunctivitis—Epirubicin—urinary bladder cancer	0.00112	0.00146	CcSEcCtD
Mometasone—Urinary tract infection—Epirubicin—urinary bladder cancer	0.00112	0.00146	CcSEcCtD
Mometasone—Upper respiratory tract infection—Doxorubicin—urinary bladder cancer	0.00112	0.00145	CcSEcCtD
Mometasone—Asthenia—Gemcitabine—urinary bladder cancer	0.00111	0.00144	CcSEcCtD
Mometasone—Pharyngitis—Methotrexate—urinary bladder cancer	0.0011	0.00143	CcSEcCtD
Mometasone—Epistaxis—Epirubicin—urinary bladder cancer	0.00109	0.00142	CcSEcCtD
Mometasone—Pruritus—Gemcitabine—urinary bladder cancer	0.00109	0.00142	CcSEcCtD
Mometasone—Nausea—Thiotepa—urinary bladder cancer	0.00109	0.00142	CcSEcCtD
Mometasone—Sinusitis—Epirubicin—urinary bladder cancer	0.00109	0.00141	CcSEcCtD
Mometasone—NR3C1—Nuclear Receptor transcription pathway—PPARG—urinary bladder cancer	0.00108	0.00925	CbGpPWpGaD
Mometasone—Gastrointestinal pain—Etoposide—urinary bladder cancer	0.00108	0.0014	CcSEcCtD
Mometasone—Pruritus—Fluorouracil—urinary bladder cancer	0.00107	0.00139	CcSEcCtD
Mometasone—CYP2C8—Biological oxidations—CYP4B1—urinary bladder cancer	0.00107	0.00916	CbGpPWpGaD
Mometasone—CYP2C8—Metapathway biotransformation—CYP4B1—urinary bladder cancer	0.00106	0.00903	CbGpPWpGaD
Mometasone—Diarrhoea—Gemcitabine—urinary bladder cancer	0.00105	0.00137	CcSEcCtD
Mometasone—NR3C1—Regulation of nuclear SMAD2/3 signaling—NCOR1—urinary bladder cancer	0.00104	0.00892	CbGpPWpGaD
Mometasone—Rhinitis—Epirubicin—urinary bladder cancer	0.00104	0.00135	CcSEcCtD
Mometasone—Abdominal pain—Etoposide—urinary bladder cancer	0.00104	0.00135	CcSEcCtD
Mometasone—Body temperature increased—Etoposide—urinary bladder cancer	0.00104	0.00135	CcSEcCtD
Mometasone—Conjunctivitis—Doxorubicin—urinary bladder cancer	0.00104	0.00135	CcSEcCtD
Mometasone—Urinary tract infection—Doxorubicin—urinary bladder cancer	0.00104	0.00135	CcSEcCtD
Mometasone—Diarrhoea—Fluorouracil—urinary bladder cancer	0.00104	0.00135	CcSEcCtD
Mometasone—Asthenia—Cisplatin—urinary bladder cancer	0.00103	0.00134	CcSEcCtD
Mometasone—Pharyngitis—Epirubicin—urinary bladder cancer	0.00103	0.00134	CcSEcCtD
Mometasone—Epistaxis—Doxorubicin—urinary bladder cancer	0.00101	0.00131	CcSEcCtD
Mometasone—NR3C1—Regulation of Androgen receptor activity—CREBBP—urinary bladder cancer	0.00101	0.00862	CbGpPWpGaD
Mometasone—Sinusitis—Doxorubicin—urinary bladder cancer	0.001	0.00131	CcSEcCtD
Mometasone—Immune system disorder—Methotrexate—urinary bladder cancer	0.001	0.0013	CcSEcCtD
Mometasone—Mediastinal disorder—Methotrexate—urinary bladder cancer	0.001	0.0013	CcSEcCtD
Mometasone—Diarrhoea—Cisplatin—urinary bladder cancer	0.000983	0.00128	CcSEcCtD
Mometasone—Vomiting—Gemcitabine—urinary bladder cancer	0.00098	0.00127	CcSEcCtD
Mometasone—NR3C1—Circadian Clock—CREBBP—urinary bladder cancer	0.000979	0.00837	CbGpPWpGaD
Mometasone—NR3C1—AP-1 transcription factor network—PLAU—urinary bladder cancer	0.000979	0.00836	CbGpPWpGaD
Mometasone—Rash—Gemcitabine—urinary bladder cancer	0.000972	0.00126	CcSEcCtD
Mometasone—Dermatitis—Gemcitabine—urinary bladder cancer	0.000971	0.00126	CcSEcCtD
Mometasone—Headache—Gemcitabine—urinary bladder cancer	0.000966	0.00126	CcSEcCtD
Mometasone—Vomiting—Fluorouracil—urinary bladder cancer	0.000964	0.00125	CcSEcCtD
Mometasone—Rhinitis—Doxorubicin—urinary bladder cancer	0.000963	0.00125	CcSEcCtD
Mometasone—Rash—Fluorouracil—urinary bladder cancer	0.000956	0.00124	CcSEcCtD
Mometasone—Dermatitis—Fluorouracil—urinary bladder cancer	0.000955	0.00124	CcSEcCtD
Mometasone—Pharyngitis—Doxorubicin—urinary bladder cancer	0.000954	0.00124	CcSEcCtD
Mometasone—Headache—Fluorouracil—urinary bladder cancer	0.00095	0.00123	CcSEcCtD
Mometasone—Asthenia—Etoposide—urinary bladder cancer	0.000944	0.00123	CcSEcCtD
Mometasone—Immune system disorder—Epirubicin—urinary bladder cancer	0.000938	0.00122	CcSEcCtD
Mometasone—Mediastinal disorder—Epirubicin—urinary bladder cancer	0.000936	0.00122	CcSEcCtD
Mometasone—Back pain—Methotrexate—urinary bladder cancer	0.000934	0.00121	CcSEcCtD
Mometasone—Pruritus—Etoposide—urinary bladder cancer	0.000931	0.00121	CcSEcCtD
Mometasone—NR3C1—AP-1 transcription factor network—ESR1—urinary bladder cancer	0.000921	0.00787	CbGpPWpGaD
Mometasone—Nausea—Gemcitabine—urinary bladder cancer	0.000916	0.00119	CcSEcCtD
Mometasone—NR3C1—BMAL1:CLOCK,NPAS2 activates circadian gene expression—EP300—urinary bladder cancer	0.000916	0.00782	CbGpPWpGaD
Mometasone—Vomiting—Cisplatin—urinary bladder cancer	0.000914	0.00119	CcSEcCtD
Mometasone—CYP2C8—Arachidonic acid metabolism—GPX1—urinary bladder cancer	0.000906	0.00774	CbGpPWpGaD
Mometasone—Rash—Cisplatin—urinary bladder cancer	0.000906	0.00118	CcSEcCtD
Mometasone—Dermatitis—Cisplatin—urinary bladder cancer	0.000905	0.00118	CcSEcCtD
Mometasone—Diarrhoea—Etoposide—urinary bladder cancer	0.000901	0.00117	CcSEcCtD
Mometasone—Nausea—Fluorouracil—urinary bladder cancer	0.0009	0.00117	CcSEcCtD
Mometasone—Back pain—Epirubicin—urinary bladder cancer	0.000875	0.00114	CcSEcCtD
Mometasone—Immune system disorder—Doxorubicin—urinary bladder cancer	0.000868	0.00113	CcSEcCtD
Mometasone—Mediastinal disorder—Doxorubicin—urinary bladder cancer	0.000866	0.00113	CcSEcCtD
Mometasone—Nausea—Cisplatin—urinary bladder cancer	0.000853	0.00111	CcSEcCtD
Mometasone—Cough—Methotrexate—urinary bladder cancer	0.000843	0.0011	CcSEcCtD
Mometasone—Vomiting—Etoposide—urinary bladder cancer	0.000837	0.00109	CcSEcCtD
Mometasone—Rash—Etoposide—urinary bladder cancer	0.00083	0.00108	CcSEcCtD
Mometasone—Dermatitis—Etoposide—urinary bladder cancer	0.000829	0.00108	CcSEcCtD
Mometasone—Headache—Etoposide—urinary bladder cancer	0.000825	0.00107	CcSEcCtD
Mometasone—NR3C1—lymph node—urinary bladder cancer	0.000824	0.0298	CbGeAlD
Mometasone—NR3C1—Regulation of nuclear SMAD2/3 signaling—CDK4—urinary bladder cancer	0.000823	0.00703	CbGpPWpGaD
Mometasone—Myalgia—Methotrexate—urinary bladder cancer	0.000822	0.00107	CcSEcCtD
Mometasone—Chest pain—Methotrexate—urinary bladder cancer	0.000822	0.00107	CcSEcCtD
Mometasone—Arthralgia—Methotrexate—urinary bladder cancer	0.000822	0.00107	CcSEcCtD
Mometasone—NR3C1—Regulation of nuclear SMAD2/3 signaling—ESR1—urinary bladder cancer	0.00082	0.007	CbGpPWpGaD
Mometasone—Back pain—Doxorubicin—urinary bladder cancer	0.000809	0.00105	CcSEcCtD
Mometasone—NR3C1—SIDS Susceptibility Pathways—ESR2—urinary bladder cancer	0.0008	0.00684	CbGpPWpGaD
Mometasone—Cough—Epirubicin—urinary bladder cancer	0.000789	0.00103	CcSEcCtD
Mometasone—Anaphylactic shock—Methotrexate—urinary bladder cancer	0.000788	0.00102	CcSEcCtD
Mometasone—Infection—Methotrexate—urinary bladder cancer	0.000783	0.00102	CcSEcCtD
Mometasone—Nausea—Etoposide—urinary bladder cancer	0.000782	0.00102	CcSEcCtD
Mometasone—Arthralgia—Epirubicin—urinary bladder cancer	0.00077	0.001	CcSEcCtD
Mometasone—Chest pain—Epirubicin—urinary bladder cancer	0.00077	0.001	CcSEcCtD
Mometasone—Myalgia—Epirubicin—urinary bladder cancer	0.00077	0.001	CcSEcCtD
Mometasone—Dry mouth—Epirubicin—urinary bladder cancer	0.000753	0.000979	CcSEcCtD
Mometasone—Anorexia—Methotrexate—urinary bladder cancer	0.000752	0.000977	CcSEcCtD
Mometasone—Anaphylactic shock—Epirubicin—urinary bladder cancer	0.000738	0.000959	CcSEcCtD
Mometasone—Infection—Epirubicin—urinary bladder cancer	0.000733	0.000953	CcSEcCtD
Mometasone—Cough—Doxorubicin—urinary bladder cancer	0.00073	0.000949	CcSEcCtD
Mometasone—Musculoskeletal discomfort—Methotrexate—urinary bladder cancer	0.000718	0.000934	CcSEcCtD
Mometasone—NR3C1—Regulation of nuclear SMAD2/3 signaling—CREBBP—urinary bladder cancer	0.000718	0.00614	CbGpPWpGaD
Mometasone—NR3C1—Adipogenesis—NCOR1—urinary bladder cancer	0.000715	0.00611	CbGpPWpGaD
Mometasone—CYP2C8—Biological oxidations—NAT2—urinary bladder cancer	0.000713	0.00609	CbGpPWpGaD
Mometasone—Myalgia—Doxorubicin—urinary bladder cancer	0.000712	0.000926	CcSEcCtD
Mometasone—Arthralgia—Doxorubicin—urinary bladder cancer	0.000712	0.000926	CcSEcCtD
Mometasone—Chest pain—Doxorubicin—urinary bladder cancer	0.000712	0.000926	CcSEcCtD
Mometasone—NR3C1—Glucocorticoid receptor regulatory network—CREBBP—urinary bladder cancer	0.000711	0.00608	CbGpPWpGaD
Mometasone—Paraesthesia—Methotrexate—urinary bladder cancer	0.000708	0.00092	CcSEcCtD
Mometasone—NR3C1—AP-1 transcription factor network—CDKN2A—urinary bladder cancer	0.000707	0.00604	CbGpPWpGaD
Mometasone—CYP2C8—Metapathway biotransformation—NAT2—urinary bladder cancer	0.000703	0.00601	CbGpPWpGaD
Mometasone—Anorexia—Epirubicin—urinary bladder cancer	0.000703	0.000914	CcSEcCtD
Mometasone—Dyspnoea—Methotrexate—urinary bladder cancer	0.000703	0.000914	CcSEcCtD
Mometasone—Dry mouth—Doxorubicin—urinary bladder cancer	0.000697	0.000905	CcSEcCtD
Mometasone—Dyspepsia—Methotrexate—urinary bladder cancer	0.000694	0.000902	CcSEcCtD
Mometasone—NR3C1—Regulation of Androgen receptor activity—EP300—urinary bladder cancer	0.000687	0.00587	CbGpPWpGaD
Mometasone—Decreased appetite—Methotrexate—urinary bladder cancer	0.000685	0.000891	CcSEcCtD
Mometasone—Anaphylactic shock—Doxorubicin—urinary bladder cancer	0.000683	0.000888	CcSEcCtD
Mometasone—Fatigue—Methotrexate—urinary bladder cancer	0.00068	0.000884	CcSEcCtD
Mometasone—Infection—Doxorubicin—urinary bladder cancer	0.000678	0.000882	CcSEcCtD
Mometasone—Pain—Methotrexate—urinary bladder cancer	0.000674	0.000877	CcSEcCtD
Mometasone—Musculoskeletal discomfort—Epirubicin—urinary bladder cancer	0.000672	0.000874	CcSEcCtD
Mometasone—NR3C1—Regulation of Androgen receptor activity—SRC—urinary bladder cancer	0.000668	0.00571	CbGpPWpGaD
Mometasone—NR3C1—Circadian Clock—EP300—urinary bladder cancer	0.000667	0.0057	CbGpPWpGaD
Mometasone—Paraesthesia—Epirubicin—urinary bladder cancer	0.000663	0.000861	CcSEcCtD
Mometasone—Dyspnoea—Epirubicin—urinary bladder cancer	0.000658	0.000855	CcSEcCtD
Mometasone—Anorexia—Doxorubicin—urinary bladder cancer	0.000651	0.000846	CcSEcCtD
Mometasone—Dyspepsia—Epirubicin—urinary bladder cancer	0.00065	0.000844	CcSEcCtD
Mometasone—Gastrointestinal pain—Methotrexate—urinary bladder cancer	0.000645	0.000838	CcSEcCtD
Mometasone—Decreased appetite—Epirubicin—urinary bladder cancer	0.000641	0.000834	CcSEcCtD
Mometasone—NR3C1—AP-1 transcription factor network—CXCL8—urinary bladder cancer	0.000641	0.00548	CbGpPWpGaD
Mometasone—NR3C1—Adipogenesis—FAS—urinary bladder cancer	0.000641	0.00547	CbGpPWpGaD
Mometasone—Fatigue—Epirubicin—urinary bladder cancer	0.000636	0.000827	CcSEcCtD
Mometasone—Pain—Epirubicin—urinary bladder cancer	0.000631	0.00082	CcSEcCtD
Mometasone—Abdominal pain—Methotrexate—urinary bladder cancer	0.000623	0.00081	CcSEcCtD
Mometasone—Body temperature increased—Methotrexate—urinary bladder cancer	0.000623	0.00081	CcSEcCtD
Mometasone—Musculoskeletal discomfort—Doxorubicin—urinary bladder cancer	0.000622	0.000809	CcSEcCtD
Mometasone—Paraesthesia—Doxorubicin—urinary bladder cancer	0.000613	0.000797	CcSEcCtD
Mometasone—NR3C1—AP-1 transcription factor network—IL2—urinary bladder cancer	0.000613	0.00524	CbGpPWpGaD
Mometasone—Dyspnoea—Doxorubicin—urinary bladder cancer	0.000609	0.000791	CcSEcCtD
Mometasone—Gastrointestinal pain—Epirubicin—urinary bladder cancer	0.000603	0.000784	CcSEcCtD
Mometasone—Dyspepsia—Doxorubicin—urinary bladder cancer	0.000601	0.000781	CcSEcCtD
Mometasone—NR3C1—AP-1 transcription factor network—CCND1—urinary bladder cancer	0.000597	0.0051	CbGpPWpGaD
Mometasone—Decreased appetite—Doxorubicin—urinary bladder cancer	0.000593	0.000772	CcSEcCtD
Mometasone—Fatigue—Doxorubicin—urinary bladder cancer	0.000589	0.000765	CcSEcCtD
Mometasone—Pain—Doxorubicin—urinary bladder cancer	0.000584	0.000759	CcSEcCtD
Mometasone—Body temperature increased—Epirubicin—urinary bladder cancer	0.000583	0.000758	CcSEcCtD
Mometasone—Abdominal pain—Epirubicin—urinary bladder cancer	0.000583	0.000758	CcSEcCtD
Mometasone—NR3C1—AP-1 transcription factor network—MMP9—urinary bladder cancer	0.00058	0.00496	CbGpPWpGaD
Mometasone—NR3C1—AP-1 transcription factor network—PTEN—urinary bladder cancer	0.000576	0.00493	CbGpPWpGaD
Mometasone—CYP2C8—Biological oxidations—HPGDS—urinary bladder cancer	0.00057	0.00487	CbGpPWpGaD
Mometasone—Asthenia—Methotrexate—urinary bladder cancer	0.000566	0.000735	CcSEcCtD
Mometasone—NR3C1—Glucocorticoid receptor regulatory network—CXCL8—urinary bladder cancer	0.000565	0.00483	CbGpPWpGaD
Mometasone—Gastrointestinal pain—Doxorubicin—urinary bladder cancer	0.000558	0.000726	CcSEcCtD
Mometasone—Pruritus—Methotrexate—urinary bladder cancer	0.000558	0.000725	CcSEcCtD
Mometasone—CYP2C8—Biological oxidations—GSTT1—urinary bladder cancer	0.000553	0.00473	CbGpPWpGaD
Mometasone—NR3C1—AP-1 transcription factor network—EP300—urinary bladder cancer	0.00055	0.0047	CbGpPWpGaD
Mometasone—NR3C1—Glucocorticoid receptor regulatory network—IL2—urinary bladder cancer	0.00054	0.00461	CbGpPWpGaD
Mometasone—Abdominal pain—Doxorubicin—urinary bladder cancer	0.00054	0.000702	CcSEcCtD
Mometasone—Body temperature increased—Doxorubicin—urinary bladder cancer	0.00054	0.000702	CcSEcCtD
Mometasone—Diarrhoea—Methotrexate—urinary bladder cancer	0.000539	0.000701	CcSEcCtD
Mometasone—CYP2C8—Arachidonic acid metabolism—PTGS2—urinary bladder cancer	0.000534	0.00456	CbGpPWpGaD
Mometasone—Asthenia—Epirubicin—urinary bladder cancer	0.000529	0.000688	CcSEcCtD
Mometasone—Pruritus—Epirubicin—urinary bladder cancer	0.000522	0.000679	CcSEcCtD
Mometasone—NR3C1—Regulation of nuclear SMAD2/3 signaling—CDKN1A—urinary bladder cancer	0.000514	0.00439	CbGpPWpGaD
Mometasone—NR3C1—Adipogenesis—PPARG—urinary bladder cancer	0.000512	0.00438	CbGpPWpGaD
Mometasone—NR3C1—Glucocorticoid receptor regulatory network—CDKN1A—urinary bladder cancer	0.000509	0.00435	CbGpPWpGaD
Mometasone—Diarrhoea—Epirubicin—urinary bladder cancer	0.000505	0.000656	CcSEcCtD
Mometasone—Vomiting—Methotrexate—urinary bladder cancer	0.000501	0.000652	CcSEcCtD
Mometasone—Rash—Methotrexate—urinary bladder cancer	0.000497	0.000646	CcSEcCtD
Mometasone—Dermatitis—Methotrexate—urinary bladder cancer	0.000497	0.000646	CcSEcCtD
Mometasone—Headache—Methotrexate—urinary bladder cancer	0.000494	0.000642	CcSEcCtD
Mometasone—NR3C1—Adipogenesis—RB1—urinary bladder cancer	0.00049	0.00419	CbGpPWpGaD
Mometasone—Asthenia—Doxorubicin—urinary bladder cancer	0.00049	0.000637	CcSEcCtD
Mometasone—NR3C1—Regulation of nuclear SMAD2/3 signaling—EP300—urinary bladder cancer	0.000489	0.00418	CbGpPWpGaD
Mometasone—NR3C1—Adipogenesis—IGF1—urinary bladder cancer	0.000486	0.00415	CbGpPWpGaD
Mometasone—NR3C1—Glucocorticoid receptor regulatory network—EP300—urinary bladder cancer	0.000484	0.00414	CbGpPWpGaD
Mometasone—Pruritus—Doxorubicin—urinary bladder cancer	0.000483	0.000628	CcSEcCtD
Mometasone—NR3C1—AP-1 transcription factor network—MYC—urinary bladder cancer	0.000479	0.00409	CbGpPWpGaD
Mometasone—Vomiting—Epirubicin—urinary bladder cancer	0.000469	0.00061	CcSEcCtD
Mometasone—Nausea—Methotrexate—urinary bladder cancer	0.000468	0.000609	CcSEcCtD
Mometasone—Diarrhoea—Doxorubicin—urinary bladder cancer	0.000467	0.000607	CcSEcCtD
Mometasone—Rash—Epirubicin—urinary bladder cancer	0.000465	0.000605	CcSEcCtD
Mometasone—Dermatitis—Epirubicin—urinary bladder cancer	0.000465	0.000604	CcSEcCtD
Mometasone—Headache—Epirubicin—urinary bladder cancer	0.000462	0.000601	CcSEcCtD
Mometasone—Nausea—Epirubicin—urinary bladder cancer	0.000438	0.00057	CcSEcCtD
Mometasone—Vomiting—Doxorubicin—urinary bladder cancer	0.000434	0.000564	CcSEcCtD
Mometasone—Rash—Doxorubicin—urinary bladder cancer	0.00043	0.00056	CcSEcCtD
Mometasone—Dermatitis—Doxorubicin—urinary bladder cancer	0.00043	0.000559	CcSEcCtD
Mometasone—Headache—Doxorubicin—urinary bladder cancer	0.000428	0.000556	CcSEcCtD
Mometasone—NR3C1—Regulation of nuclear SMAD2/3 signaling—MYC—urinary bladder cancer	0.000426	0.00364	CbGpPWpGaD
Mometasone—NR3C1—SIDS Susceptibility Pathways—CREBBP—urinary bladder cancer	0.000425	0.00363	CbGpPWpGaD
Mometasone—CYP2C8—Metabolism of lipids and lipoproteins—CYP4B1—urinary bladder cancer	0.000412	0.00352	CbGpPWpGaD
Mometasone—Nausea—Doxorubicin—urinary bladder cancer	0.000406	0.000527	CcSEcCtD
Mometasone—NR3C1—AP-1 transcription factor network—TP53—urinary bladder cancer	0.000393	0.00336	CbGpPWpGaD
Mometasone—CYP2C8—Biological oxidations—GSTP1—urinary bladder cancer	0.000383	0.00328	CbGpPWpGaD
Mometasone—CYP2C8—Metapathway biotransformation—GSTP1—urinary bladder cancer	0.000378	0.00323	CbGpPWpGaD
Mometasone—Fluoxymesterone—ESR1—urinary bladder cancer	0.000369	0.478	CrCbGaD
Mometasone—CYP2C8—Biological oxidations—GSTM1—urinary bladder cancer	0.000352	0.00301	CbGpPWpGaD
Mometasone—NR3C1—Adipogenesis—CDKN1A—urinary bladder cancer	0.000352	0.00301	CbGpPWpGaD
Mometasone—CYP2C8—Metapathway biotransformation—GSTM1—urinary bladder cancer	0.000347	0.00297	CbGpPWpGaD
Mometasone—NR3C1—Glucocorticoid receptor regulatory network—TP53—urinary bladder cancer	0.000347	0.00296	CbGpPWpGaD
Mometasone—NR3C1—Generic Transcription Pathway—ESR2—urinary bladder cancer	0.000338	0.00289	CbGpPWpGaD
Mometasone—NR3C1—SIDS Susceptibility Pathways—CXCL8—urinary bladder cancer	0.000338	0.00289	CbGpPWpGaD
Mometasone—NR3C1—SIDS Susceptibility Pathways—EP300—urinary bladder cancer	0.00029	0.00247	CbGpPWpGaD
Mometasone—NR3C1—Adipogenesis—TNF—urinary bladder cancer	0.000272	0.00232	CbGpPWpGaD
Mometasone—NR3C1—Generic Transcription Pathway—NCOR1—urinary bladder cancer	0.000261	0.00223	CbGpPWpGaD
Mometasone—NR3C1—SIDS Susceptibility Pathways—TNF—urinary bladder cancer	0.000235	0.00201	CbGpPWpGaD
Mometasone—CYP2C8—Metabolism—GSTZ1—urinary bladder cancer	0.000235	0.00201	CbGpPWpGaD
Mometasone—CYP2C8—Metabolism—GSTO2—urinary bladder cancer	0.000223	0.0019	CbGpPWpGaD
Mometasone—CYP2C8—Metabolism—NAT1—urinary bladder cancer	0.000223	0.0019	CbGpPWpGaD
Mometasone—CYP2C8—Metabolism of lipids and lipoproteins—HPGDS—urinary bladder cancer	0.000219	0.00187	CbGpPWpGaD
Mometasone—NR3C1—Generic Transcription Pathway—ESR1—urinary bladder cancer	0.000205	0.00175	CbGpPWpGaD
Mometasone—CYP2C8—Metabolism—UGT2B7—urinary bladder cancer	0.000204	0.00174	CbGpPWpGaD
Mometasone—NR3C1—Generic Transcription Pathway—PPARG—urinary bladder cancer	0.000187	0.0016	CbGpPWpGaD
Mometasone—NR3C1—Gene Expression—SMC1A—urinary bladder cancer	0.000187	0.0016	CbGpPWpGaD
Mometasone—CYP2C8—Metabolism—CYP4B1—urinary bladder cancer	0.000183	0.00157	CbGpPWpGaD
Mometasone—NR3C1—Generic Transcription Pathway—CREBBP—urinary bladder cancer	0.00018	0.00154	CbGpPWpGaD
Mometasone—Triamcinolone—PTGS2—urinary bladder cancer	0.000175	0.227	CrCbGaD
Mometasone—CYP2C8—Metabolism—SLC19A1—urinary bladder cancer	0.000173	0.00148	CbGpPWpGaD
Mometasone—CYP2C8—Metabolism—PRSS3—urinary bladder cancer	0.000169	0.00144	CbGpPWpGaD
Mometasone—NR3C1—Gene Expression—ESR2—urinary bladder cancer	0.000163	0.00139	CbGpPWpGaD
Mometasone—Betamethasone—PTGS2—urinary bladder cancer	0.000143	0.186	CrCbGaD
Mometasone—CYP2C8—Metabolism of lipids and lipoproteins—NCOR1—urinary bladder cancer	0.000135	0.00116	CbGpPWpGaD
Mometasone—CYP2C8—Metabolism—TYMP—urinary bladder cancer	0.000135	0.00115	CbGpPWpGaD
Mometasone—CYP2C8—Metabolism of lipids and lipoproteins—GPX1—urinary bladder cancer	0.00013	0.00111	CbGpPWpGaD
Mometasone—NR3C1—Gene Expression—NCOR1—urinary bladder cancer	0.000126	0.00107	CbGpPWpGaD
Mometasone—CYP2C8—Metabolism—NAT2—urinary bladder cancer	0.000122	0.00104	CbGpPWpGaD
Mometasone—NR3C1—Gene Expression—ERCC2—urinary bladder cancer	0.000118	0.00101	CbGpPWpGaD
Mometasone—NR3C1—Generic Transcription Pathway—MYC—urinary bladder cancer	0.000107	0.000911	CbGpPWpGaD
Mometasone—CYP2C8—Metabolism—RRM2—urinary bladder cancer	0.000105	0.0009	CbGpPWpGaD
Mometasone—NR3C1—Gene Expression—ESR1—urinary bladder cancer	9.87e-05	0.000843	CbGpPWpGaD
Mometasone—CYP2C8—Metabolism—ENO2—urinary bladder cancer	9.75e-05	0.000833	CbGpPWpGaD
Mometasone—CYP2C8—Metabolism—HPGDS—urinary bladder cancer	9.75e-05	0.000833	CbGpPWpGaD
Mometasone—CYP2C8—Metabolism of lipids and lipoproteins—PPARG—urinary bladder cancer	9.69e-05	0.000828	CbGpPWpGaD
Mometasone—CYP2C8—Metabolism—GSTT1—urinary bladder cancer	9.46e-05	0.000808	CbGpPWpGaD
Mometasone—CYP2C8—Metabolism of lipids and lipoproteins—CREBBP—urinary bladder cancer	9.31e-05	0.000796	CbGpPWpGaD
Mometasone—NR3C1—Gene Expression—PPARG—urinary bladder cancer	9e-05	0.000769	CbGpPWpGaD
Mometasone—NR3C1—Gene Expression—CREBBP—urinary bladder cancer	8.65e-05	0.000739	CbGpPWpGaD
Mometasone—Dexamethasone—PTGS2—urinary bladder cancer	8.35e-05	0.108	CrCbGaD
Mometasone—CYP2C8—Metabolism—NQO1—urinary bladder cancer	7.86e-05	0.000672	CbGpPWpGaD
Mometasone—CYP2C8—Metabolism of lipids and lipoproteins—PTGS2—urinary bladder cancer	7.62e-05	0.000652	CbGpPWpGaD
Mometasone—CYP2C8—Metabolism of lipids and lipoproteins—PTEN—urinary bladder cancer	6.65e-05	0.000568	CbGpPWpGaD
Mometasone—CYP2C8—Metabolism—GSTP1—urinary bladder cancer	6.55e-05	0.00056	CbGpPWpGaD
Mometasone—CYP2C8—Metabolism of lipids and lipoproteins—EP300—urinary bladder cancer	6.34e-05	0.000542	CbGpPWpGaD
Mometasone—CYP2C8—Metabolism—TYMS—urinary bladder cancer	6.09e-05	0.000521	CbGpPWpGaD
Mometasone—CYP2C8—Metabolism—GSTM1—urinary bladder cancer	6.02e-05	0.000515	CbGpPWpGaD
Mometasone—CYP2C8—Metabolism—NCOR1—urinary bladder cancer	6.02e-05	0.000515	CbGpPWpGaD
Mometasone—CYP2C8—Metabolism—GPX1—urinary bladder cancer	5.77e-05	0.000493	CbGpPWpGaD
Mometasone—CYP2C8—Metabolism—ERCC2—urinary bladder cancer	5.66e-05	0.000484	CbGpPWpGaD
Mometasone—CYP2C8—Metabolism—MTHFR—urinary bladder cancer	5.32e-05	0.000455	CbGpPWpGaD
Mometasone—NR3C1—Gene Expression—MYC—urinary bladder cancer	5.13e-05	0.000439	CbGpPWpGaD
Mometasone—CYP2C8—Metabolism—PPARG—urinary bladder cancer	4.32e-05	0.000369	CbGpPWpGaD
Mometasone—CYP2C8—Metabolism—CREBBP—urinary bladder cancer	4.15e-05	0.000354	CbGpPWpGaD
Mometasone—CYP2C8—Metabolism—PTGS2—urinary bladder cancer	3.4e-05	0.00029	CbGpPWpGaD
Mometasone—CYP2C8—Metabolism—PTEN—urinary bladder cancer	2.96e-05	0.000253	CbGpPWpGaD
Mometasone—CYP2C8—Metabolism—EP300—urinary bladder cancer	2.82e-05	0.000241	CbGpPWpGaD
